Efficacy and Safety of Lornoxicam in Patients With Acute Coronary Syndrome
Prospective Randomized Double-center Study of Nonsteroidal Antinflammatory Drug Lornoxicam in Patients With Acute Coronary Syndrome Without Persistent ST- Segment Elevation
StatusCompleted No Results Posted
Indication/ConditionAcute Coronary Syndrome
The purpose of this study is to determine whether nonsteroidal antiinflammatory drug lornoxicam in combination with low dose aspirin (100mg/day) is effective and safe in patients with Acute Coronary Syndrome without persistent ST-segment elevation.
Nonsteroidal Antiinflammatory drugs (NSAIDs) are the most frequently prescribed drugs in the world. There are a lot of controversial information published during recent years about NSAID cardiosafety. It is still unclear do NSAIDs develop cardioprotective or cardiotoxic effects in acute and chronic heart disease patients. Aim of the study was to investigate safety and efficacy of Lornoxicam, nonselective COX-inhibitor, in patients with acute coronary syndrome without ST-segment elevation (NSTEACS) and to evaluate the influence of Lornoxicam on C-reactive protein (CRP) and IL-6, IL-10 levels.
Inclusion Criteria: Unstable angina verified during first 48 hours after admitting to the hospital or Acute Miocardial infarction without St-segment elevation verified during first 48 hours after admitting to the hospital Exclusion Criteria: High risk of bleeding of any location Any kind of acute and active inflammatory process (excluding acute coronary syndrome) Aspirin or NSAID Intolerability No informed consent Acute peptic stomach or duodenum ulcer Acute or chronic renal failure (serum creatinin >300 mmol/l) Acute cerebrovascular bleeding